Logo image of KZIA

KAZIA THERAPEUTICS-SPON ADR (KZIA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:KZIA - US48669G3039 - ADR

10.55 USD
+0.59 (+5.92%)
Last: 11/28/2025, 7:43:10 PM
10.38 USD
-0.17 (-1.61%)
After Hours: 11/28/2025, 7:43:10 PM
Fundamental Rating

1

Taking everything into account, KZIA scores 1 out of 10 in our fundamental rating. KZIA was compared to 533 industry peers in the Biotechnology industry. KZIA has a bad profitability rating. Also its financial health evaluation is rather negative. KZIA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year KZIA has reported negative net income.
KZIA had a negative operating cash flow in the past year.
KZIA had negative earnings in each of the past 5 years.
KZIA had a negative operating cash flow in each of the past 5 years.
KZIA Yearly Net Income VS EBIT VS OCF VS FCFKZIA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M -20M -25M

1.2 Ratios

KZIA has a Return On Assets of -158.60%. This is amonst the worse of the industry: KZIA underperforms 86.14% of its industry peers.
Industry RankSector Rank
ROA -158.6%
ROE N/A
ROIC N/A
ROA(3y)-179.5%
ROA(5y)-124.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KZIA Yearly ROA, ROE, ROICKZIA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400 600

1.3 Margins

KZIA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KZIA Yearly Profit, Operating, Gross MarginsKZIA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200K -400K -600K -800K -1M

More info and screens

0

2. Health

2.1 Basic Checks

KZIA has more shares outstanding than it did 1 year ago.
KZIA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, KZIA has a worse debt to assets ratio.
KZIA Yearly Shares OutstandingKZIA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200K 400K 600K 800K 1M
KZIA Yearly Total Debt VS Total AssetsKZIA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

2.2 Solvency

KZIA has an Altman-Z score of -14.98. This is a bad value and indicates that KZIA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -14.98, KZIA is doing worse than 80.52% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -14.98
ROIC/WACCN/A
WACCN/A
KZIA Yearly LT Debt VS Equity VS FCFKZIA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 0.21 indicates that KZIA may have some problems paying its short term obligations.
The Current ratio of KZIA (0.21) is worse than 95.13% of its industry peers.
KZIA has a Quick Ratio of 0.21. This is a bad value and indicates that KZIA is not financially healthy enough and could expect problems in meeting its short term obligations.
KZIA's Quick ratio of 0.21 is on the low side compared to the rest of the industry. KZIA is outperformed by 94.76% of its industry peers.
Industry RankSector Rank
Current Ratio 0.21
Quick Ratio 0.21
KZIA Yearly Current Assets VS Current LiabilitesKZIA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 93.01% over the past year.
Looking at the last year, KZIA shows a very negative growth in Revenue. The Revenue has decreased by -95.09% in the last year.
Measured over the past years, KZIA shows a quite strong growth in Revenue. The Revenue has been growing by 11.58% on average per year.
EPS 1Y (TTM)93.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.76%
Revenue 1Y (TTM)-95.09%
Revenue growth 3Y278.64%
Revenue growth 5Y11.58%
Sales Q2Q%-98.18%

3.2 Future

Based on estimates for the next years, KZIA will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.17% on average per year.
KZIA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 378.99% yearly.
EPS Next Y57.51%
EPS Next 2Y24.48%
EPS Next 3Y25.93%
EPS Next 5Y15.17%
Revenue Next Year-25.37%
Revenue Next 2Y-32.53%
Revenue Next 3Y144.92%
Revenue Next 5Y378.99%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
KZIA Yearly Revenue VS EstimatesKZIA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
KZIA Yearly EPS VS EstimatesKZIA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

KZIA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KZIA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KZIA Price Earnings VS Forward Price EarningsKZIA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KZIA Per share dataKZIA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

A more expensive valuation may be justified as KZIA's earnings are expected to grow with 25.93% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.48%
EPS Next 3Y25.93%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KZIA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KAZIA THERAPEUTICS-SPON ADR

NASDAQ:KZIA (11/28/2025, 7:43:10 PM)

After market: 10.38 -0.17 (-1.61%)

10.55

+0.59 (+5.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2025-11-07/amc
Earnings (Next)N/A N/A
Inst Owners10.68%
Inst Owner Change9.73%
Ins Owners8.48%
Ins Owner ChangeN/A
Market Cap17.62M
Revenue(TTM)114.00K
Net Income(TTM)-28.41M
Analysts82.5
Price Target16.83 (59.53%)
Short Float %6.33%
Short Ratio0.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)17.86%
PT rev (3m)17.86%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)22.68%
EPS NY rev (3m)88.86%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.53
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-13.7
EYN/A
EPS(NY)-0.94
Fwd EYN/A
FCF(TTM)-4.56
FCFYN/A
OCF(TTM)-4.56
OCFYN/A
SpS0.92
BVpS-1.49
TBVpS-7.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -158.6%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-179.5%
ROA(5y)-124.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.21
Quick Ratio 0.21
Altman-Z -14.98
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)93.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.76%
EPS Next Y57.51%
EPS Next 2Y24.48%
EPS Next 3Y25.93%
EPS Next 5Y15.17%
Revenue 1Y (TTM)-95.09%
Revenue growth 3Y278.64%
Revenue growth 5Y11.58%
Sales Q2Q%-98.18%
Revenue Next Year-25.37%
Revenue Next 2Y-32.53%
Revenue Next 3Y144.92%
Revenue Next 5Y378.99%
EBIT growth 1Y-55.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y8.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.03%
OCF growth 3YN/A
OCF growth 5YN/A

KAZIA THERAPEUTICS-SPON ADR / KZIA FAQ

What is the fundamental rating for KZIA stock?

ChartMill assigns a fundamental rating of 1 / 10 to KZIA.


What is the valuation status of KAZIA THERAPEUTICS-SPON ADR (KZIA) stock?

ChartMill assigns a valuation rating of 0 / 10 to KAZIA THERAPEUTICS-SPON ADR (KZIA). This can be considered as Overvalued.


Can you provide the profitability details for KAZIA THERAPEUTICS-SPON ADR?

KAZIA THERAPEUTICS-SPON ADR (KZIA) has a profitability rating of 0 / 10.